Roche Obesity Drug Shows 22.5% Weight Loss as It Seeks to Catch Up With Lilly, Novo

Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage ‌trial, underpinning the Swiss… Reuters Health Information

Read the full article on medscape.com